ArticleTranslational pediatrics2026
Obesity-related palmitic acid exacerbates IL-13-induced mucus phenotype in 16HBE airway epithelial cells via AMPK suppression.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucus hypersecretion and obesity are two prevalent comorbidities that independently worsen childhood asthma outcomes. However, the metabolic mechanisms by which obesity-related factors interact with type 2 (T2) inflammatory signals to exacerbate airway epithelial mucus phenotype remain poorly understood. This study aimed to investigate whether palmitic acid (PA), a representative obesity-related saturated fatty acid, amplifies interleukin-13 (IL-13)-induced mucus phenotype in human bronchial epithelial cells and to determine whether the AMP-activated protein kinase (AMPK) axis mediates this interaction. Methods: We stimulated 16HBE human bronchial epithelial cells with IL-13 (10 ng/mL, 72 h), PA (100 µM, 48 h), or combined IL-13 and PA exposure, in which PA was added during the final 48 h of IL-13 treatment. We activated AMPK pharmacologically with AICAR (1 mM) and suppressed AMPK genetically through small interfering RNA (siRNA)-mediated PRKAA1 knockdown. We quantified Results: Combined IL-13 and PA stimulation markedly elevated MUC5AC and CLCA1 mRNA and protein expression beyond IL-13 alone (P<0.001). In addition, combined stimulation further increased IL-8 secretion (P<0.001), indicating a stronger pro-inflammatory epithelial response after combining inflammatory and metabolic stimuli. In parallel, the p-ACC/ACC ratio, an indicator of AMPK activity, was lowest after combined IL-13 and PA exposure (P<0.001). AMPK activation with AICAR partially reversed MUC5AC, CLCA1, and IL-8 upregulation and restored ZO-1 continuity (P<0.001), whereas PRKAA1 knockdown further aggravated MUC5AC expression (P<0.01) and reduced p-ACC levels (P<0.05). Conclusions: PA amplifies IL-13-induced airway epithelial mucus phenotype through suppression of the AMPK axis. AMPK may represent a potential therapeutic target for mucus hypersecretion in obesity-related childhood asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.